Antigen Characterized By Name Or Molecular Weight Patents (Class 424/156.1)
-
Patent number: 6492497Abstract: The invention provides specific binding members, for example in the form of antibody variable domains, based on the CDR3 sequences of the antibody VH regions of SL15 (SEQ ID NO:4) and JT182 (SEQ ID NO:10). The antibodies have strong neutralizing activity for TGF&bgr;1 and are useful in treating conditions associated with excess TGF&bgr;1 activity, such as fibrosis, immune responses and tumor progression.Type: GrantFiled: April 28, 2000Date of Patent: December 10, 2002Assignee: Cambridge Antibody Technology LimitedInventors: Julia Elizabeth Thompson, Simon Nicholas Lennard, Alison Jane Wilton, Peta Sally Helena Braddock, Sarah Leila Du Fou, John Gerald McCafferty, Louise Anne Conroy, Philip Ronald Tempest
-
Patent number: 6491914Abstract: An anti-idiotypic monoclonal antibody that is specific against the N-glycolyl residues of gangliosides, particularly those expressed by cancer cells. The monoclonal antibody is useful as an immunomodulator for cancer treatment. Specifically, the anti-Id monoclonal antibody of the present invention is capable of inducing a predominant anti-idiotypic response in xenogeneic models. The anti-idiotypic monoclonal antibody also exerts a protective effect against malignant tumors in animals.Type: GrantFiled: November 24, 1999Date of Patent: December 10, 2002Assignee: Centro de Inmunologia MolecularInventors: Ana Maria Vázguez López, Rolando Pérez Rodriguez, Eladio Iglesis Guerra, Alexis Pérez, Gumersinda Bombino Lopez, Irene Beausoleil Delgado
-
Patent number: 6485970Abstract: The present invention relates generally to immunointeractive molecules and their use inter alia in the detection and/or purification of T-cell antigen binding molecules (TABMs). The ability to determine the presence and levels of particular TABMs provides a useful diagnostic procedures for a variety of disease conditions.Type: GrantFiled: May 10, 2000Date of Patent: November 26, 2002Inventors: Robert E. Cone, George M. Georgiou, Colin H. Little
-
Publication number: 20020165363Abstract: The invention relates to a therapeutic agent for cachexia comprising, as an active ingredient, a substance capab;le of inhibiting the binding between a parathyroid hormone related protein (PTHrP) and a receptor thereof.Type: ApplicationFiled: November 12, 1999Publication date: November 7, 2002Inventors: KOH SATO, TOSHIAKI TSUNENARI, KIMIE ISHII
-
Patent number: 6458356Abstract: Anti-Her2 antibodies which induce apoptosis in Her2 expressing cells are disclosed. The antibodies are used to “tag” Her2 overexpressing tumors for elimination by the host immune system. Also disclosed are hybridoma cell lines producing the antibodies, methods for treating cancer using the antibodies, and pharmaceutical compositions.Type: GrantFiled: March 23, 1998Date of Patent: October 1, 2002Assignee: Amgen Inc.Inventors: Tsutomu Arakawa, Yoshiko Kita
-
Patent number: 6455043Abstract: New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise in particular administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkins lymphomas.Type: GrantFiled: August 11, 1999Date of Patent: September 24, 2002Assignee: IDEC Pharmaceuticals CorporationInventor: Antonio J. Grillo-López
-
Patent number: 6447776Abstract: The present invention describes monoclonal antibodies which are useful for the specific detection of diffuse gastric carcinoma. Further embodiments describe therapeutic and diagnostic means for the detection and for the therapy of diffuse gastric carcinomas.Type: GrantFiled: July 23, 1997Date of Patent: September 10, 2002Assignee: GSF Forschungszentrum fur Umwelt und Gesundheit GmbHInventors: Heinz Höfler, Karl-Friedrich Becker, Elisabeth Kremmer, Manfred Eulitz, Christoph Schuhmacher
-
Patent number: 6444207Abstract: Disclosed is a method for treating a gastrointestinal tumor by administering a murine antibody which specifically binds an epitope of 17-1A antigen.Type: GrantFiled: September 16, 1994Date of Patent: September 3, 2002Assignee: Centocor, Inc.Inventors: Hubert J. P. Schoemaker, Richard A. Carrano
-
Patent number: 6399063Abstract: A method of inhibiting growth of tumor cells which overexpress a growth factor receptor or growth factor by treatment of the cells with antibodies which inhibit the growth factor receptor function, is disclosed. A method of treating tumor cells with antibodies which inhibit growth factor receptor function, and with cytotoxic factor(s) such as tumor necrosis factor, is also disclosed. By inhibiting growth factor receptor functions tumor cells are rendered more susceptible to cytotoxic factors.Type: GrantFiled: September 14, 1998Date of Patent: June 4, 2002Assignee: Genentech, Inc.Inventors: Robert M. Hudziak, H. Michael Shepard, Axel Ullrich, Brian M. Fendly
-
Patent number: 6399061Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies. Preferred anti-CD20 antibodies are the monoclonal anti-body secreted by ATCC Deposit No. HB11388 and the chimeric anti-CD20 antibody secreted by transfectoma TCAE8 accorded ATCC Deposit No. 69119.Type: GrantFiled: June 7, 1995Date of Patent: June 4, 2002Assignee: IDEC Pharmaceutical CorporationInventors: Darrell R. Anderson, Nabil Hanna, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
-
Publication number: 20020065398Abstract: New humanized and chimeric monoclonal antibodies that recognize EGF-R and comprise an artificial sequence at least of the FRs of the heavy chain variable region of a human immunoglobulin.Type: ApplicationFiled: December 21, 1998Publication date: May 30, 2002Inventors: CRISTINA M.M.A. DEL RIO, ROLANDO PEREZ RODRIGUEZ, ERNESTO MORENO FRIAS
-
Patent number: 6395272Abstract: Multispecific multivalent molecules which are specific to an Fc receptor (FcR), and therapeutic uses and therapeutic uses and methods for making the molecules are described.Type: GrantFiled: June 22, 1998Date of Patent: May 28, 2002Assignee: Mederex, Inc.Inventors: Yashwant M. Deo, Joel Goldstein, Robert Graziano, Chezian Somasundaram
-
Patent number: 6387371Abstract: A method of inhibiting growth of tumor cells which overexpress a growth factor receptor or growth factor by treatment of the cells with antibodies which inhibit the growth factor receptor function, is disclosed. A method of treating tumor cells with antibodies which inhibit growth factor receptor function, and with cytotoxic factor(s) such as tumor necrosis factor, is also disclosed. By inhibiting growth factor receptor functions tumor cells are rendered more susceptible to cytotoxic factors.Type: GrantFiled: June 25, 1999Date of Patent: May 14, 2002Assignee: Genentech, Inc.Inventors: Robert M. Hudziak, H. Michael Shepard, Axel Ullrich, Brian M. Fendly
-
Publication number: 20020052480Abstract: Recombinant antibody proteins are provided that specifically bind fibroblast activation protein alpha (FAP&agr;) and comprise framework modifications resulting in the improved producibility in host cells. The invention also relates to the use of said antibodies for diagnostic and therapeutic purposes and methods of producing said antibodies.Type: ApplicationFiled: April 29, 1999Publication date: May 2, 2002Inventors: JOHN EDWARD PARK, PILAR GARIN-CHESA, UWE BAMBERGER, WOLFGANG J. RETTIG, OLIVIER LEGER, JOSE WILLIAM SALDANHA
-
Patent number: 6379953Abstract: Disclosed are compositions and methods for accelerating the differentiation of human MSCs into the osteogenic lineage with resultant enhanced de novo bone formation. This makes possible improved methods for bone defect repair. Thus, one aspect of the invention is a method for accelerating the differentiation of ALCAM-bearing hMSCs into the osteogenic lineage by contacting such hMSCs with a ligand that binds to activated leukocyte-cell adhesion molecule (ALCAM) on a single hMSC. Preferably, the ligand is a Fab fragment of a monoclonal antibody expressed by the hybridoma of ATCC Accession No. NB 11789.Type: GrantFiled: December 1, 1999Date of Patent: April 30, 2002Assignee: Osiris Therapeutics, Inc.Inventors: Scott P. Bruder, Neelam Jaiswal
-
Patent number: 6379668Abstract: A method for the prevention or reversal of transplant rejection, or for therapy for autoimmune diseases, is provided comprising administering compounds such as monoclonal antibodies, that bind specifically to one or more preselected CD45R leukocyte antigens.Type: GrantFiled: June 17, 1999Date of Patent: April 30, 2002Assignees: Research Corporation Technologies, Inc., Alimmune, LLCInventors: Andrew I. Lazarovits, Sibrand Poppema
-
Patent number: 6368596Abstract: This invention discloses monoclonal antibodies (MAbs) which have little or no signaling activity as monomers become potent anti-tumor agents when they are converted into homoconjugates. The homoconjugates exert anti-growth activity by signaling G0/G1 arrest or apoptosis, depending upon which cell surface molecule they bind. This activity is specific and does not require an Fc portion. These conjugates are potent, anti-tumor agents.Type: GrantFiled: July 8, 1998Date of Patent: April 9, 2002Assignee: Board of Regents, The University of Texas SystemInventors: Maria-Ana Ghetie, Jonathan W. Uhr, Ellen S. Vitetta
-
Patent number: 6365157Abstract: Monoclonal antibodies that specifically bind to an extracellular domain of a flt-1 receptor and neutralize activation of the receptor are provided. In vitro and in vivo methods of using these antibodies are also provided.Type: GrantFiled: September 22, 1999Date of Patent: April 2, 2002Assignee: ImClone Systems, Inc.Inventors: Patricia Rockwell, Neil I. Goldstein
-
Publication number: 20020037288Abstract: A therapeutic agent for lymphatic tumors (excluding myeloma) comprising as an active ingredient an antibody that specifically binds to a protein having the amino acid sequence as set forth in SEQ ID NO: 1 and that has a cytotoxic activity.Type: ApplicationFiled: August 11, 1999Publication date: March 28, 2002Inventors: YASUO KOISHIHARA, YASUSHI YOSHIMURA
-
Patent number: 6361775Abstract: The invention encompasses methods and compositions for inducing an immune response in an anti-Gal synthesizing animal including viral and tumor antigens manipulated to express &agr;-galactosyl epitopes.Type: GrantFiled: October 15, 1998Date of Patent: March 26, 2002Assignees: Medical College of Pennsylvania, Hahnemann UniversityInventors: Uri Galili, Patricia M. Repik
-
Publication number: 20020031515Abstract: Methods for treating a subject with a cancer that is characterized by overexpression of HER2 receptor protein using a combination of interleukin-2 (IL-2) or variant thereof and at least one anti-HER2 antibody or fragment thereof are provided. These anti-tumor agents are administered as two separate pharmaceutical compositions, one containing IL-2 (or variant thereof), the other containing at least one anti-HER2 antibody (or fragment thereof), according to a dosing regimen. Administering of these two agents together potentiates the effectiveness of the anti-HER2 antibody alone, resulting in a positive therapeutic response that is improved with respect to that observed with this anti-tumor agent.Type: ApplicationFiled: May 14, 2001Publication date: March 14, 2002Inventors: Michael A. Caligiuri, Neal J. Meropol, Richard L. Schilsky
-
Patent number: 6350861Abstract: The present invention provides methods for producing mutationally-altered immunoglobulins and compositions containing such mutationally-altered immunoglobulins, wherein the mutationally-altered immunoglobulins have at least one mutation that alters the pattern of glycosylation in a variable region and thereby modifies the affinity of the immunoglobulin for a preselected antigen. The methods and compositions of the invention provide immunoglobulins that possess increased affinity for antigen. Such glycosylation-altered immunoglobulins are suitable for diagnostic and therapeutic applications.Type: GrantFiled: May 23, 1997Date of Patent: February 26, 2002Assignees: Protein Design Labs, Inc., Memorial Sloan Kettering Cancer CenterInventors: Man Sung Co, David A. Scheinberg, Cary L. Queen
-
Patent number: 6348581Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.Type: GrantFiled: February 18, 1998Date of Patent: February 19, 2002Assignee: The Dow Chemical CompanyInventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
-
Publication number: 20020018775Abstract: The present invention relates to monoclonal antibodies specific for a cell receptor specific for human stem cell factor (hSCF) as well as pharmaceutical compositions containing such monoclonal antibodies and uses of such monoclonal antibodies.Type: ApplicationFiled: July 13, 1999Publication date: February 14, 2002Inventors: VIRGINIA C BROUDY, NANCY LIN
-
Patent number: 6346249Abstract: The invention is directed to methods of reducing the effects of cancer in a subject by administering to said subject a pharmaceutically effective amount of an anti-cancer agent conjugated to an inmmunoglobulin product which comprises one or more novel complementarity determining region and framework regions.Type: GrantFiled: April 4, 2000Date of Patent: February 12, 2002Assignees: Ludwig Institute for Cancer Research, The Scripps Research InstituteInventors: Carlos F. Barbas, III, Christoph Rader, Gerd Ritter, Sydney Welt, Lloyd J. Old
-
Patent number: 6342587Abstract: The invention is directed to novel CDRs and immunoglobulin products that bind to A33 antigens and methods for their use. The invention also involves a method for making humanized antibodies, using a rabbit as a host animal, and phage display library methodologies, and the antibodies themselves. The methodology is useful, for example, in generating humanized antibodies against molecules associated with cancer, such as A33, which is associated with colon cancer.Type: GrantFiled: October 22, 1999Date of Patent: January 29, 2002Assignees: Ludwig Institute for Cancer Research, The Scripps Research InstituteInventors: Carlos F. Barbas, III, Christoph Rader, Gerd Ritter, Sydney Welt, Lloyd J. Old
-
Publication number: 20020009451Abstract: Hybridomally produced monoclonal antibodies specifically immunoreactive with the glycoprotein carrying the CA 125 epitope. Monoclonal antibodies recognize both high and low molecular weight subunits of the antigen, and identify the antigen in the cytoplasm and the extracellular matrix of CA 125 producing cells. An immunoassay for the detection of CA 125 utilizing the monoclonal antibodies is described.Type: ApplicationFiled: April 29, 1998Publication date: January 24, 2002Inventor: TIMOTHY J. O'BRIEN
-
Patent number: 6306393Abstract: B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 or CD19 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 and/or anti-CD19 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.Type: GrantFiled: May 10, 1999Date of Patent: October 23, 2001Assignee: Immunomedics, Inc.Inventor: David M. Goldenberg
-
Patent number: 6291496Abstract: Cancer associated with overexpression of class I family of receptor tyrosine kinases, e.g., with overexpresssion of HER-2/neu or overexpression of epidermal growth factor receptor, are treated with strongly binding PPAR&ggr; ligands.Type: GrantFiled: December 27, 1999Date of Patent: September 18, 2001Inventors: Andrew J. Dannenberg, Kotha Subbaramaiah
-
Patent number: 6287562Abstract: The invention provides methods for inhibiting the growth of a cell bearing a LewisY antigen. The methods involve contacting the cell with a composition comprising an Fv region of a light chain of a monoclonal antibody selected from B1, B3, and B5, and the Fv region of a humanized heavy chain of a monoclonal antibody independently selected from B1, B3, and B5, provided that if the heavy and the light chains are from the same antibody, the residue at position 95 of the heavy chain is a serine, and, if the antibody chain is from B3, the residue at position 4 of the light chain can be a leucine and the residue at position 82b of the heavy chain can be an arginine. The Fv regions are joined to an effector molecule selected from a chemotherapeutic agent, a toxin, a radioisotope, and a liposome loaded with a chemotherapeutic agent. In preferred embodiments, the heavy chain and the light chain are recombinantly fused, and the Fv regions are recombinantly fused to a toxin.Type: GrantFiled: January 8, 1999Date of Patent: September 11, 2001Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Ira Pastan, Itai Benhar, Eduardo A. Padlan, Sun-Hee Jung, Byungkook Lee
-
Patent number: 6274143Abstract: The present invention provides methods of delaying development of HMFG-associated tumors using the anti-idiotype antibody 11D10, particularly in high-risk individuals having low tumor burden.Type: GrantFiled: June 11, 1998Date of Patent: August 14, 2001Inventors: Malaya Chatterjee, Kenneth A. Foon
-
Patent number: 6267960Abstract: The present invention provides methods for inhibiting the growth of prostate tumor cells expressing Prostate Stem Cell Antigen (PSCA), the methods comprising administering to a patient a monoclonal antibody which binds specifically to the extracellular domain of PSCA in an amount effective to inhibit growth of the prostate tumor cells.Type: GrantFiled: March 10, 1998Date of Patent: July 31, 2001Assignee: The Regents of the University of CaliforniaInventors: Robert E. Reiter, Owen N. Witte
-
Patent number: 6267959Abstract: It is the objective and purpose of the present invention to provide a monoclonal antibody having the property of causing apoptosis on myeloid cells. This invention relates to a monoclonal antibody having the property of causing apoptosis on myeloid cells, and fragments thereof, and furthermore relates to a hybridoma producing the monoclonal antibody. Since the monoclonal antibodies of the present invention are useful as antibodies recognizing and identifying antigens causing apoptosis on myeloid cells specifically and besides have the property of causing apoptosis on myeloid cells, they may be used as medicine useful in the field of remedies for myelocytic leukemia utilizing the property.Type: GrantFiled: September 17, 1998Date of Patent: July 31, 2001Assignee: Chugai Seiyaku Kabushiki KaishaInventor: Naoshi Fukushima
-
Patent number: 6261535Abstract: The present invention relates generally to methods and compositions for targeting the vasculature of solid tumors using immunological- and growth factor-based reagents. In particular aspects, antibodies carrying diagnostic or therapeutic agents are targeted to the vasculature of solid tumor masses through recognition of tumor vasculature-associated antigens, such as, for example, through endoglin binding, or through the specific induction of endothelial cell surface antigens on vascular endothelial cells in solid tumors.Type: GrantFiled: December 8, 1998Date of Patent: July 17, 2001Assignee: The University of Texas System Board of RegentsInventors: Philip E. Thorpe, Francis J. Burrows
-
Patent number: 6248327Abstract: A method of modulating angiogenesis in a vertebrate subject, the method comprising administering to the vertebrate subject an ECRTP/DEP-1 receptor activity-modulating amount of a composition, whereby an ECRTP/DEP-1 receptor within the vertebrate subject is contacted by the composition; and modulating angiogenesis through the contacting of the ECRTP/DEP-1 receptor with the composition. Optionally, the composition includes a monoclonal antibody which preferentially binds the ECRTP/DEP-1 receptor.Type: GrantFiled: September 11, 1998Date of Patent: June 19, 2001Assignee: Vanderbilt UniversityInventors: Thomas O. Daniel, Takamune Takahashi
-
Patent number: 6241985Abstract: The invention concerns methods and compositions for intiating and/or enhancing an immune response by contacting a binding reagent with a soluble antigen, wherein the binding reagent-antigen pair generates an immune response to the antigen.Type: GrantFiled: March 20, 1998Date of Patent: June 5, 2001Assignee: Altarex Corp.Inventors: Ragupathy Madiyalakan, Antoine A. Noujaim, Richard P. Baum, Birgit Schultes
-
Patent number: 6231855Abstract: Anti-anthracycline antibiotic monoclonal antibodies are useful as antidotes of the anthracycline antibiotics themselves, as well as for the treatment of anthracycline extravasation lesions and alopecia.Type: GrantFiled: May 4, 1993Date of Patent: May 15, 2001Assignee: Istituto Nazionale per lo Studio e la Cura Dei TumoriInventors: Mario Ghione, Andrea Balsari, Maria Ines Colnaghi
-
Patent number: 6217866Abstract: Hybridoma cell lines producing monoclonal antibodies specific to the human epidermal growth factor receptor are disclosed. The antibodies are capable of inhibiting the growth of human tumor cells expressing human epidermal growth factor receptors. Therapeutic uses of these monoclonal antibodies by themselves and in combination with anti-neoplastic agents are also disclosed.Type: GrantFiled: June 7, 1995Date of Patent: April 17, 2001Assignee: Rhone-Poulenc Rorer International (Holdings), Inc.Inventors: Joseph Schlessinger, David Givol, Francoise Bellot, Richard Kris, George A. Ricca, Christopher Cheadle, Victoria J. South
-
Patent number: 6217868Abstract: The invention provides for the production of several humanized murine antibodies specific for the antigen FB5, which is recognized by the murine antibody FB5. The FB5 antigen is expressed on the luminal surface of vascular endothelial cells of a wide range of malignant tumors. The invention also provides for numerous polynucleotide encoding humanized FB5 specific antibodies, expression vectors for producing humanized FB5 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized FB5 specific antibodies. Additionally, the invention provides methods of treating cancer using FB5 specific antibodies.Type: GrantFiled: November 2, 1998Date of Patent: April 17, 2001Assignee: Ludwig Institute for Cancer ResearchInventors: Thomas Paul Wallace, Francis Carr, Wolfgang J. Rettig, Pilar Garin-Chesa, Lloyd J. Old
-
Patent number: 6207152Abstract: Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer using the HGF receptor antagonists are also provided.Type: GrantFiled: February 17, 1998Date of Patent: March 27, 2001Assignee: Genentech, Inc.Inventors: Ralph H. Schwall, Kelly H. Tabor
-
Patent number: 6203793Abstract: Disclosed is a method for treating tissue necrosis (loss) in an animal. Tissue necrosis is treated by providing the subject with an anti-adhesion cell agent capable of binding an ICAM-1 antigen, a CD18 antigen, an L-selectin agent, a CD44 antigen, a P-selectin antigen, a VCAM-1 antigen, an ICAM-2 antigen, or a fragment thereof. Also provided is a method for preventing thermal-related tissue loss or necrosis, particularly the thermal injury and progressive tissue necrosis which results from a burn injury. Thermal-related tissue injury surrounding a thermal injury site is inhibited or prevented by providing an animal with an anti-adhesion agent, such as an anti-CD18 antibody, an anti-ICAM-1 antibody, or a mixture or fragment thereof. A method for inhibiting/preventing scarring attendant healing of a thermal injury is also disclosed.Type: GrantFiled: April 2, 1997Date of Patent: March 20, 2001Assignee: Board of Regents of the University of Texas SystemInventors: Peter Lipsky, William Mileski
-
Patent number: 6197297Abstract: A monoclonal antibody which is specific to a polypeptide having a molecular weight of 18, 500±3,000 daltons on SDS-PAGE and a pI of 4.9±1.0 on chromatofocusing. The monoclonal antibody is obtainable from hybridomas and can be used for the purification and detection of the polypeptide. The polypeptide strongly induces the IFN-&ggr; production by immunocompetent cells with only a small amount, and does not cause serious side effects even when administered to human in a relatively-high dose.Type: GrantFiled: November 15, 1995Date of Patent: March 6, 2001Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Toshio Kunikata, Mutsuko Taniguchi, Keizo Kohno, Masashi Kurimoto
-
Patent number: 6193969Abstract: A method of neutralizing TNF&agr; in a patient benefiting from such neutralizing, comprising administering to the patient IgG Fab fragment reactive towards TNF&agr;. Suitably, the patient is suffering from septic shock or from the symptoms of septic shock. It is preferred if the Fab fragment is derived from polyclonal IgG.Type: GrantFiled: March 10, 1995Date of Patent: February 27, 2001Assignee: Protherics Inc.Inventor: John Landon
-
Patent number: 6190640Abstract: The invention involves the therapeutic use of humanized antibodies, fragments, etc., which bind to the antigen A33. These antibody molecules are useful in the treatment of various neoplasias, including colon cancer. Various modes of administration, and doses are described.Type: GrantFiled: November 19, 1996Date of Patent: February 20, 2001Assignees: Ludwig Institute for Cancer Research, Sloan-Kettering Institute for Cancer ResearchInventors: Sydney Welt, Gerd Ritter, Leonard Cohen, Clarence Williams, Jr., Elizabeth Carswell Richards, Mary John, Lloyd J. Old
-
Patent number: 6183744Abstract: B-Cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.Type: GrantFiled: March 12, 1998Date of Patent: February 6, 2001Assignee: Immunomedics, Inc.Inventor: David M. Goldenberg
-
Patent number: 6184357Abstract: The present invention provides a human prostate-specific kallikrein (HPSK) and polynucleotides which identify and encode HPSK. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPSK and a method for producing HPSK. The invention also provides for agonists, antibodies, or antagonists specifically binding HPSK, and their use, in the prevention and treatment of diseases associated with the expression of HPSK. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HPSK for the treatment of diseases associated with the expression of HPSK. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HPSK.Type: GrantFiled: March 3, 1999Date of Patent: February 6, 2001Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Surya K. Goli